---
title: Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying
  or gene addition therapy during the first year of life
date: '2024-05-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38772209/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240522182830&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Treated patients with SMA type 1 have heterogeneous cognitive
  function with 55 % of patients showing deficits. Risk factors for cognitive impairment
  in our cohort were male gender and need for assisted ventilation or feeding support.
  Therefore, cognitive assessment should be included in the standard of care to allow
  early identification of deficits and potential therapeutic ...'
disable_comments: true
---
CONCLUSION: Treated patients with SMA type 1 have heterogeneous cognitive function with 55 % of patients showing deficits. Risk factors for cognitive impairment in our cohort were male gender and need for assisted ventilation or feeding support. Therefore, cognitive assessment should be included in the standard of care to allow early identification of deficits and potential therapeutic ...